Company intelligence / Profile preview

Bionorica ethics

Germany

Ownership: Private
Development stage: Other

Overview

Bionorica ethics GmbH, emerged from Delta-9-Pharma GmbH in 2007, was a German biotech company focused on cannabinoid therapeutic development. It brought a key cannabis-derived prescription drug to the German market in 2002 and researched active ingredients from the cannabis flower for nearly two decades. It was later rebranded as C³ Cannabinoid Compound Company and acquired by Canopy Growth.

Therapeutic areas: OncologyNeurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Bionorica ethics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bionorica ethics.

Explore the full profile